Nicotinamide adenine dinucleotide, a coenzyme critical for cellular energy metabolism that declines with age. NAD+ precursors like NMN and NR are studied as longevity interventions.

Mechanistic target of rapamycin, a key nutrient-sensing pathway that regulates cell growth and aging. Inhibiting mTOR (e.g., with rapamycin) has shown lifespan extension in multiple organisms.

A class of drugs that selectively eliminate senescent (aged, dysfunctional) cells to reduce inflammation and improve tissue function.

What is Epigenetic clock?

A biomarker based on DNA methylation patterns that estimates biological age, often more predictive of health outcomes than chronological age.

The period of life spent in good health, free from chronic diseases and disability associated with aging.

An immunosuppressant drug that inhibits the mTOR pathway. Research shows rapamycin may extend lifespan and improve age-related health outcomes in multiple species.

What is Biological age?

A measure of how well or poorly your body is functioning relative to your chronological age, assessed through biomarkers such as DNA methylation, telomere length, and blood panels.

What is Caloric restriction?

A dietary regimen that reduces calorie intake without malnutrition. Caloric restriction is one of the most studied interventions shown to extend lifespan across species.

Protective caps at the ends of chromosomes that shorten with each cell division. Telomere length is associated with aging and age-related diseases.

A state in which cells permanently stop dividing but resist death, accumulating with age and secreting inflammatory factors that damage surrounding tissue.

A second-generation epigenetic clock that predicts time to death and is considered one of the most accurate measures of biological aging.

What is Inflammaging?

Chronic, low-grade inflammation that increases with age and contributes to the development of age-related diseases including cardiovascular disease, diabetes, and neurodegeneration.

The large-scale study of proteins in biological systems. In longevity research, proteomics identifies blood protein signatures that predict biological age and disease risk.

What is Yamanaka factors?

A set of four transcription factors (Oct4, Sox2, Klf4, c-Myc) that can reprogram adult cells to a pluripotent state. Partial reprogramming with Yamanaka factors is being explored to reverse cellular aging.

Nicotinamide mononucleotide, a precursor to NAD+ that is widely studied as a supplement to boost cellular energy and combat age-related decline.

A gene-editing technology that allows precise modifications to DNA. In longevity research, CRISPR is used to study and potentially modify genes associated with aging.

Cognition Therapeutics to update investors at Needham virtual conference

Cognition Therapeutics is poised to share pivotal updates on its Alzheimer’s disease and dementia with Lewy bodies programs, as President and CEO Lisa Ricciardi is set to present at the 25th Annual Needham Virtual Healthcare Conference on April 13, 2026. A focal point of the presentation will be the lead candidate, zervimesine (CT1812), currently undergoing evaluation in the Phase 2 START trial targeting patients with mild cognitive impairment (MCI) and early Alzheimer’s disease. The company has previously reported promising outcomes from Phase 2 studies involving dementia with Lewy bodies (DLB), mild-to-moderate Alzheimer’s, and geographic atrophy associated with dry age-related macular degeneration (AMD).

The significance of zervimesine lies in its strong efficacy signals demonstrated in the Phase 2 SHIMMER study for DLB, which suggests a potential breakthrough in treating psychosis associated with this condition. The favorable safety profile reported in clinical trials further enhances its therapeutic potential, making it a candidate for late-stage trials aimed at addressing DLB psychosis specifically. The adoption of zervimesine as the United States Adopted Name (USAN) underscores its recognition within the scientific community and paves the way for future regulatory discussions.

The implications of this development are substantial for the field of aging and neurodegenerative research. The advancement of zervimesine into late-stage trials could accelerate the timeline for effective treatments in Alzheimer’s and DLB, shifting the paradigm towards a more targeted approach in managing these complex conditions. As Cognition Therapeutics continues to build on its clinical findings, the outcomes of these trials may inform future drug development strategies and enhance our understanding of cognitive decline in aging populations.

Source: longevity.technology